The FDA is considering a first approval of a deuterated drug, and large pharmaceutical companies have started to incorporate 'heavy hydrogen' into novel candidates.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov 15, 219–221 (2016). https://doi.org/10.1038/nrd.2016.63
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2016.63
This article is cited by
-
Transition-metal-free silylboronate-mediated cross-couplings of organic fluorides with amines
Nature Communications (2023)
-
A general synthesis of azetidines by copper-catalysed photoinduced anti-Baldwin radical cyclization of ynamides
Nature Communications (2022)
-
[18F]Difluorocarbene for positron emission tomography
Nature (2022)
-
Organophotocatalytic selective deuterodehalogenation of aryl or alkyl chlorides
Nature Communications (2021)
-
Semiconductor photocatalysis to engineering deuterated N-alkyl pharmaceuticals enabled by synergistic activation of water and alkanols
Nature Communications (2020)